Kezar Life Sciences (id:8266 KZR)
7.50 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 6:10:22 PM)
Exchange closed, opens in 15 hours 19 minutes
About Kezar Life Sciences
Market Capitalization 54.43M
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
| Headquarters (address) |
4000 Shoreline Court South San Francisco 94080 CA United States |
| Phone | 650 822 5600 |
| Website | https://www.kezarlifesciences.com |
| Employees | 58 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | KZR |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 5.20 - 11.40 |
| Market Capitalization | 54.43M |
| P/E trailing | -0.536 |
| P/E forward | -0.713 |
| Price/Sale | 7.78 |
| Price/Book | 0.289 |
| Beta | 0.217 |
| EPS | -13.50 |
| EPS United States (ID:6, base:3402) | 24.22 |